Business Context and Reporting Period
This Form 6-K filing by GSK plc (GSK) reports a transaction in the company's own shares conducted on March 24, 2026. The filing was submitted on March 25, 2026. The transaction was executed by BNP Paribas SA as part of GSK's existing share buyback programme, pursuant to a non-discretionary agreement announced on February 17, 2026.
Key Financial Metrics and Transaction Details
The filing details a specific repurchase event rather than full-period financial results. Key metrics for the March 24, 2026 transaction include:
- Shares Purchased: 500,000 ordinary shares of 31½ pence each.
- Price Range: Lowest price paid was 1,933.00p; highest price paid was 1,967.00p.
- Average Price: Volume-weighted average price (VWAP) was 1,949.05p.
- Trading Venues: Purchases were executed across BATE, CHIX, and XLON.
- Cumulative Programme Activity: Since February 17, 2026, the company has purchased 14,511,521 ordinary shares.
Material Changes and Capital Structure
Following the March 24 transaction, GSK's capital structure was updated as follows:
- Treasury Shares: The company now holds 254,402,615 ordinary shares in treasury.
- Shares in Issue: There are 4,061,773,663 ordinary shares in issue (excluding treasury shares).
- Voting Rights: The total number of voting rights is 4,061,773,663.
- Treasury Voting Percentage: The percentage of voting rights attributable to treasury shares is 6.26%.
The filing does not provide data on revenue, profit, cash flow, margins, or debt levels, as it is a disclosure of a specific share transaction.
Guidance, Outlook, and Risks
The filing contains no new financial guidance or management commentary regarding operational outlook. It includes a standard cautionary statement noting that forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from projections. Investors are directed to the "Risk Factors" section of GSK's Annual Report on Form 20-F for 2025 for a detailed description of these risks.
Key Facts for Investor Verification
- Verify the total cost of the buyback programme by calculating the cumulative spend since February 17, 2026, using the disclosed share counts and average prices.
- Confirm the current market price of GSK shares relative to the VWAP of 1,949.05p paid on March 24, 2026.
- Monitor the remaining authorization under the buyback programme to assess future capital return potential.
- Review the 2025 Form 20-F for the specific risk factors referenced in the cautionary statement.